

We should not underestimate the role of biofilms in persistent (chronic) bronchitis – Authors' reply

Marsh, Robyn L.; Binks, Michael J.; Smith-Vaughan, Heidi C.; Janka, Maxine; Clark, Sharon;
Richmond, Peter; Chang, Anne B.; Thornton, Ruth B.

Published in:
The Lancet Microbe

DOI:
[10.1016/S2666-5247\(22\)00189-6](https://doi.org/10.1016/S2666-5247(22)00189-6)

Published: 01/09/2022

Document Version
Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):

Marsh, R. L., Binks, M. J., Smith-Vaughan, H. C., Janka, M., Clark, S., Richmond, P., Chang, A. B., & Thornton, R. B. (2022). We should not underestimate the role of biofilms in persistent (chronic) bronchitis – Authors' reply. *The Lancet Microbe*, 3(9), e648. [https://doi.org/10.1016/S2666-5247\(22\)00189-6](https://doi.org/10.1016/S2666-5247(22)00189-6)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

We should not underestimate the role of biofilms in persistent (chronic) bronchitis

Authors' reply

We thank Mark Lloyd Everard for his comments and interest in our paper.¹ The main point raised relates to the risk of false negative biofilm results and our interpretation therefore minimising the perceived requirement for anti-biofilm treatments. We agree that there is a need to understand whether anti-biofilm treatments improve outcomes in patients with protracted bacterial bronchitis or bronchiectasis; however, data are scarce. Indeed, we are unaware of any guidelines for paediatric protracted bacterial bronchitis and bronchiectasis that recommend anti-biofilm treatments.

Everard raises important points about sampling issues long known to limit respiratory microbiology studies. We considered bronchoalveolar lavage to be the optimal method for our study as it is the gold standard for assessing airway microbiology in young children, its specimens are less prone to upper airway contamination than sputum, and it samples more of the airways than the protected specimen brush.²⁻⁴ As noted in our

Article,¹ we also considered the use of microscopy a limitation of our study due to the method potentially lacking sensitivity. The issues highlighted by Everard point to an important overarching challenge facing the field: what is the best way to diagnose biofilm-associated airway infections? The solution is not yet clear; however, as noted in our paper, we recommend the development of a biofilm test suitable for use in clinical laboratories as a research priority.

We thank Everard for suggesting squamous metaplasia as another potential explanation for squamous epithelial cell-associated biofilms. Children in our study were not assessed for squamous metaplasia and we are unaware of any study that has systematically examined squamous metaplasia among children with protracted bacterial bronchitis or bronchiectasis. As upper airway contamination, microaspiration, and squamous metaplasia are all potentially plausible explanations for the presence of squamous cell-associated biofilms in bronchoalveolar lavage specimens, we recommend differentiating these biofilms from non-squamous epithelial cell biofilms to achieve a nuanced understanding of the role of biofilms in chronic airway infections.

The declaration of interests remains the same as in the original Article.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

**Robyn L Marsh, Michael J Binks, Heidi C Smith-Vaughan, Maxine Janka, Sharon Clark, Peter Richmond, Anne B Chang, Ruth B Thornton*
 robyn.marsh@menzies.edu.au

Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia (RLM, MJB, HCS-V, ABC); School of Medicine, Griffith University, Southport, QLD, Australia (HCS-V); Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, WA, Australia (MJ, SC, PR, RBT); School of Medicine, Division of Paediatrics (SC, PR) and School of Biomedical Science (RBT), University of Western Australia, Perth, WA, Australia; Department of Respiratory and Sleep Medicine, Queensland Children's Hospital, Brisbane, QLD, Australia (ABC); Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane, QLD, Australia (ABC)

- 1 Marsh RL, Binks MJ, Smith-Vaughan HC, et al. Prevalence and subtyping of biofilms present in bronchoalveolar lavage from children with protracted bacterial bronchitis or non-cystic fibrosis bronchiectasis: a cross-sectional study. *Lancet Microbe* 2022; **3**: e215-23.
- 2 Kahn FW, Jones JM. Diagnosing bacterial respiratory infection by bronchoalveolar lavage. *J Infect Dis* 1987; **155**: 862-69.
- 3 Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. *Am J Respir Crit Care Med* 2012; **186**: 857-65.
- 4 Dickson RP, Erb-Downward JR, Freeman CM, et al. Bacterial topography of the healthy human lower respiratory tract. *mBio* 2017; **8**: e02287-16.



Published Online
 July 4, 2022
[https://doi.org/10.1016/S2666-5247\(22\)00189-6](https://doi.org/10.1016/S2666-5247(22)00189-6)